



FOR IMMEDIATE RELEASE

UltraGreen.ai Expands Asia Presence with Regulatory Approvals for IC-Flow™ Imaging System V2 in India, Thailand, Philippines, and Bangladesh

Singapore, 12 March 2026 — UltraGreen.ai Limited (SGX:ULG) (“UltraGreen” or the “Company”), a global leader in fluorescence-guided surgery and digital health solutions, today announced that its IC-Flow™ Imaging System V2 has received regulatory approval across multiple South and Southeast Asian markets, bringing the system’s global regulatory footprint to 45 territories.

This development supports the Company’s strategy to broaden access to its fluorescence imaging technologies in the Asia Pacific (APAC) region.

The approvals include:

- **India** – Registered with Central Drugs Standard Control Organisation (CDSCO), Government of India
- **Thailand** – Approved by the Thai Medical Device Control Division
- **Philippines** – Approved by the Centre for Device Regulation, Health and Research (CDRRHR)
- **Bangladesh** – Approved by the Directorate General of Drug Administration (DGDA)

These regulatory clearances authorise UltraGreen to commercialise the IC-Flow™ Imaging System V2 in the respective countries in accordance with local regulatory requirements.

The IC-Flow™ Imaging System V2 is a hand-held near-infrared (NIR) fluorescence imaging platform developed to support intraoperative visualisation during open surgical procedures. Across the newly approved territories, the system is used to assess tissue perfusion and flap circulation for plastic and micro-reconstructive surgery, support organ transplant procedures, and visualise lymphatic flow.

“This series of regulatory approvals reflects our ongoing commitment to expanding access to compliant fluorescence imaging technologies across the region,” said **Declan Cassells, Chief Operating Officer of UltraGreen**. “Each approval enables us to actively engage with healthcare institutions, distributors, and clinical partners while ensuring adherence to local regulatory frameworks.”

Quek Mei Ling, Chief Business Officer (APAC) of UltraGreen, commented, “South and Southeast Asia represent important and growing healthcare markets. These milestones strengthen our ability to build long-term partnerships, support clinical education initiatives, and advance responsible commercialisation in alignment with quality and compliance standards.”

The clearances build on the Company’s recent approvals for Verdyne (Indocyanine Green, pharmaceutical product) in the Philippines and the IC-Flow™ Imaging System V2 in Malaysia. With these latest milestones, UltraGreen continues to reinforce its regulatory presence across multiple jurisdictions. The IC-Flow™ Imaging System V2 is also approved in Singapore and New Zealand within

the APAC region, as well as in the United States and Europe, reflecting the Company's broader global expansion strategy.

About IC-Flow™ Imaging System V2

The IC-Flow™ Imaging System V2 is a handheld near-infrared (NIR) camera, that visualises and records quality tissue fluorescence, providing real-time imaging during open surgical procedures to evaluate tissue perfusion and support the visualisation of lymphatic flow. The IC-Flow™ Imaging System is now approved in 45 territories worldwide.

About UltraGreen.ai

UltraGreen.ai Limited (SGX: ULG) is a global leader in fluorescence-guided surgery, pioneering vertical AI tools for precision surgery through data-driven fluorescence imaging solutions. The Company's flagship Indocyanine Green ("ICG") product — marketed as IC-GREEN® in the United States, Indocyanine Green for Injection, USP in the United States and Canada, and Verdye outside North America — is the most widely used fluorescence imaging agent globally.

UltraGreen offers an integrated fluorescence imaging ecosystem that empowers surgeons with enhanced visualisation and real-time perfusion insights, supporting greater surgical precision and improved patient outcomes.

Headquartered in Singapore, UltraGreen operates globally, with a strong presence in the United States and Ireland, as well as offices across Asia-Pacific.

For more information, visit www.ultragreen.ai

For more information, please contact:

Mr Roger Ng

Head of Investor Relations

Email: Roger.ng@Ultragreen.ai

On behalf of UltraGreen.ai

H/Advisors Klareco

Email: Klareco-Ultragreen@h-advisors.global